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Aims: Endothelin (ET)-1 is the best known potent vasoconstrictor and has been implicated in pathogenesis of
sepsis-associated acute kidney injury (AKI) in human or lipopolysaccharide (LPS)-induced AKI in animalmodels.
We have previously shown that ET-1 is highly up-regulated in renal tissues and in plasma after LPS administra-
tion. Here, we investigated whether landiolol hydrochloride, an ultra-short-acting beta-blocker, can play an im-
portant role in ameliorating levels of LPS-induced up-regulation of renal HIF-1α–ET-1 system and inﬂammatory
cytokines in a rat model of endotoxemia.
Main methods:Male Wistar rats at 8 weeks of age were either administered with: a) lipopolysaccharide (LPS)
only for three hours (3 h) or b) LPS, followed by continuous administration of landiolol for 3 h; c) third group
was only treated with vehicle.
Key ﬁndings:At 3 h after LPS administration therewas: a)minimal injury in kidney tissues; b) circulatory levels of
creatinine, blood urea nitrogen and NGAL increased and c) expression of inﬂammatory cytokines, such as TNF-α,
IL-6 and iNOS increased at the level of both circulatory and renal tissues. In addition, LPS signiﬁcantly induced
renal expression of ET-1 and HIF-1α compared to control. Finally, treatment of LPS-administered rats with
landiolol for 3 h normalized elevated serum markers of renal injury and up-regulated levels of renal HIF-1α–
ET-1 system with normalization of TNF-α.
Signiﬁcance: Taken together, these data led us to conclude that landiolol ameliorates the up-regulation ofHIF-1α–
ET-1 system in minimally morphologically-injured kidney and normalizes biomarkers of renal injury in early
hours of endotoxemia of a rat model.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Sepsis is a clinical syndrome caused by severe infection and is charac-
terized by a systemic inﬂammatory reaction with organ dysfunction
(Hotchkiss and Karl, 2003; Vandijck et al., 2006). Organ failure is known
to occur in 33.6% of septic shock patients (Martin et al., 2003). The sys-
temic inﬂammatory response may be initiated by entry of bacterial lipo-
polysaccharide (LPS) or other microbial components into the lymphatic
and circulatory systems. Once the sepsis cascade is triggered, a systemicitical Care Medicine, Faculty of
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. This is an open access article underinﬂammatory response will ensue and, if unregulated, will lead to multi-
ple organ failure. Acute renal failure as well as acute kidney injury (AKI)
are common and critical complications of sepsis and septic shock
(Palevsky et al., 2008). The combination of acute renal failure and sepsis
contributes to the high mortality rate as much as 70% compared to 45%
mortality among patients with acute renal failure alone (Schrier and
Wang, 2004).
The mechanisms underlying renal dysfunction are still not fully
understood, but could involve hypercytokinemia, endothelial and epi-
thelial cell injury and circulating factors (Lopes et al., 2007; Palm et al.,
2004). Levels of cytokines, including interleukin-6 (IL-6) and tumor ne-
crosis factor-alpha (TNF-α), are signiﬁcantly higher in sepsis-related
acute renal failure patients compared to non-sepsis cases (Murugan
et al., 2010). If uncorrected, pathogenesis takes a worse turn following
endothelial activation, as it leads to increased capillary permeability, sys-
temic vasodilation, and, ultimately, multi-organ failure (MOF). In addi-
tion, a previous study suggests that changes in the vasoconstrictor tone
of the afferent and efferent arterioles may be crucial in inducing the lossthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
348 Y. Ogura et al. / Life Sciences 118 (2014) 347–356of glomerular ﬁltration rate (GFR), contributing to the pathogenesis of
sepsis-related acute renal failure (Bellomo et al., 2011; Langenberg et al.,
2006).
Endothelin (ET)-1, a potent vasoconstrictor (Yanagisawa et al.,
1988), has been implicated in the pathogenesis of sepsis and is induced
by hypoxia inducible factor 1-alpha (HIF-1α), which is a transcription
factor that responds to hypoxia. Plasma levels of ET-1 have been
shown to be signiﬁcantly higher in septic patients (Battistini et al.,
1996) and their levels (ET-1) have a clear correlation with morbidity
and mortality in septic patients, suggesting an involvement of ET in
the pathogenesis of septic shock in humans (Pittet et al., 1991). Further,
it has been suggested that ET contributes to the dysfunction of several
vital organ systems in septic shock. In the kidney, ET-1 may affect func-
tion of renal microcirculation by inducing constriction in afferent and
efferent arterioles mediated by the ET receptor, ET-A (Schildroth et al.,
2011). In addition, in rats with diabetic renal injury, selective antago-
nism of ET-A reduces macrophage inﬁltration, suggesting that ET-A ac-
tivation also contributes to renal inﬂammation (Sasser et al., 2007). In
our previous study we have shown that ET-1 is highly upregulated in
renal tissues, as well as in plasma after LPS administration and there is
a potential imbalance in the expression of vaso-regulatory molecules
of renal tissue (Yamaguchi et al., 2006).
On the other hand, landiolol hydrochloride, an ultra-short-acting
(a half-life of 4min) and highly cardio-selective beta-1 blocker, recently
has become useful in treating various medical problems, such as man-
agement of acute rapid heart rate and prevention of atrial ﬁbrillation
after cardiac surgery (Iguchi et al., 1992). The drug has already been ap-
proved as an emergency treatment of supraventricular tachyarrhythmia
in patients in Japan. Landiolol has also been reported to have a lesser
effect on blood pressure compared to esmolol (Mio, 2006). Recent stud-
ies have demonstrated that co-treatmentwith landiolol protects against
acute lung injury and cardiac dysfunction in a rat model of LPS-induced
systemic inﬂammation,which is associatedwith signiﬁcant reduction in
serum levels of the inﬂammation mediator, HMGB-1 and histological
lung damage (Hagiwara et al., 2009). However, these earlier studies
have not investigated whether landiolol has renal protective effects in
endotoxemia.
In the current study, we investigated whether landiolol hydro-
chloride can play an important role in ameliorating elevated renal levels
of LPS-induced HIF-1α–ET-1 system and inﬂammatory cytokines and
renal injury markers in the early hours of endotoxemia of a rat model.
Materials and methods
Animal preparation
Male Wistar rats (200–250 g, 8 weeks old) were used in all experi-
ments. Endotoxemiawas induced by the intra-peritoneal (IP) administra-
tion of bacterial LPS from Escherichia coli 055: B5 (15 mg/kg), dissolved in
sterile saline (Yamaguchi et al., 2006). The rats were (n = 59) random-
ized into group 1 (control, n = 17), group 2 (control + landiolol hydro-
chloride, n = 8), group 3 (LPS, n = 17) and group 4 (LPS + landiolol
hydrochloride, n = 17).
Groups 1 and 2 received an equal volume of vehicle (sterile saline;
2 ml/body), without LPS. And, it should benoted that LPS (15 mg/kg, in-
traperitoneal) was administered at time 0 in groups 3 and 4, and then
the ratswere killed after 3 h. However, for groups 2 and 4, 15min before
LPS or vehicle administration, landiolol hydrochloride was adminis-
tered continuously intravenously (100 μg/kg/min). From our pilot stud-
ies, we found this to be the minimal dose of landiolol, which can
normalize the LPS-induced hyperdynamic state in the early hours of
endotoxemia. In addition, we wanted to use the dose of landiolol at a
level that exerts minimal effects on blood pressure in endotoxemic rats.
All rats were killed by Nembutal (sodium pentobarbital, IP, 80 mg/kg
bodyweight) at 3 h after LPS or vehicle only. The blood sampleswere col-
lected from a polyproprene tube catheter inserted into the left carotidartery for blood gas analysis, and renal tissues were harvested gently,
snap-frozen in liquid nitrogen, and stored at−80 °C. All animals received
care and the experimental procedureswere approved by the Animal Care
and Use Committee of University of Tsukuba.
Measurements of hemodynamic parameters
Rats were anesthetized with isoﬂurane inhalation (1.5%, 1 l/min)
and a microtip pressure transducer catheter (SPC-320, Millar Instru-
ments, Houston, TX, USA)was inserted into the left carotid artery, as de-
scribed in our previous study (Yamaguchi et al., 2006) at the endof the 3
h experimental protocol. Next, arterial blood pressure and heart rate
were monitored with a pressure transducer (model SCK-590, Gould,
Ohio, USA) and recorded with the use of a polygraph system (ampliﬁer,
AP-601G, Nihon Kohden, Tokyo, Japan; Tachometer, AT-601G, Nihon
Kohden; and thermal-pen recorder, WT-687G, Nihon Kohden). It is im-
portant to note here that all the experimental animals went through the
same type of anesthetic conditions during hemodynamic measurements.
Echocardiography
Echocardiographywasperformedusing a Vevo 2100high-frequency
ultrasound system (VisualSonics, Inc., Ontario, Canada), which includes
an integrated rail system for consistent positioning of the ultrasound
probe (Yang et al., 2013) at the end of the 3 h experimental protocol.
The fur from the chest was electrically clipped and a gel was applied
prior to shaving. The animalswere placed on a heatingpad and connect-
ed to an electrocardiogram (ECG), while rectal temperature was moni-
tored to maintain a body temperature of 38 ± 0.1 °C. A 35 MHz linear
transducer (VisualSonics, RMV 707, Inc., Ontario, Canada) was used
for imaging. An optimal parasternal long axis (LAX) cine loop (i.e. visu-
alization of both the mitral and aortic valves, and maximum distance
between the aortic valve and the cardiac apex) of N1000 frames/s was
acquired using the ECG-gated kilohertz visualization technique. The
probe was then rotated 90° and positioned 6 mm below the mitral an-
nulus, i.e. at the level of the papillary muscles. Three parasternal short-
axis (SAX) M-mode sequences were stored. Fractional shortening (FS)
was calculated in the M-mode image as FS = (EDD − ESD) / EDD,
where EDD and ESD are the end-diastolic and end-systolic diameters,
respectively.
Measurement of kidney injury markers
Serum creatinine levels were measured using Creatinine (Serum)
Assay Kit from Wako Pure Chemical Industries (LTD, Osaka, Japan).
Blood urea nitrogen (BUN) levels were measured using Urea Nitrogen
(BUN) Colorimetric Detection Kit (Arbor Assays, Ann Arbor, Michigan).
Plasma urea levels were measured using Urea Colorimetric Assay Kit
(BioVision, Milpitas, California). Lastly, creatine phosphate kinase
(CPK) activities were measured using Creatine Kinase Activity Colori-
metric Assay Kit (BioVision Milpitas, California).
Histopathology examination
Histopathological studies were performed to determine the extent of
renal micro-morphological injury in LPS-induced endotoxemia and re-
covery by administration of landiolol hydrochloride. Kidney tissues
were ﬁxed in 4% buffered formalin solution, dehydrated, embedded in
parafﬁn, and then sliced into 5-μm-thick sections. After deparafﬁnization,
slides were stained by hematoxylin and eosin (H&E).
Enzyme-linked immunosorbent assay for plasma and renal NGAL, TNF-α,
IL-6, iNOS and ET-1
The concentration of each respective protein/peptide of interest in
plasma/serum and renal tissue extracts was determined using the
following kits: plasma and renal neutrophil gelatinase-associated
lopocalin (NGAL)which is a highly predictive biomarker of acute kidney
injury (Han et al., 2012) (Abcam, Cambridge, UK) and serum and renal
levels of TNF-α, IL-6, inducible nitric oxide synthase (iNOS) and ET-1
Table 1
Blood gas analysis, hemodynamic parameters and biochemical parameters.
Control LPS LPS + landiolol
n 8 7 8
pH 7.40 ± 0.07 7.43 ± 0.06 7.44 ± 0.06
PaO2, torr 98.6 ± 2.7 87.3 ± 5.8⁎ 100.3 ± 10.3
PaCO2, torr 37.4 ± 2.0 36.4 ± 1.8⁎ 30.4 ± 3.2⁎
BE, mmol/l −0.9 ± 0.9 −4.0 ± 2.6 −5.4 ± 2.2⁎
Lac, mmol/l 0.8 ± 0.3 2.9 ± 0.6⁎ 1.8 ± 0.2⁎,#
HCO3−, mmol/l 25.4 ± 0.6 23.4 ± 1.2⁎ 22.1 ± 1.2⁎
Systolic BP, mm Hg 125 ± 4 108 ± 6⁎ 102 ± 8⁎
Diastolic BP, mm Hg 84 ± 6 70 ± 4⁎ 67 ± 4⁎
Heart rate, bpm 461 ± 14 510 ± 21⁎ 441 ± 10#
FS, % 41.1 ± 1.1 45.6 ± 1.3⁎ 41.6 ± 1.3#
Plasma Urea, nmol/μl 1.44 ± 0.02 1.70 ± 0.23 1.47 ± 0.12
Plasma CPK, mU/ml 19.9 ± 5.3 22.9 ± 5.1 21.9 ± 5.7
Serum TNF-α, pg/ml 12.6 ± 2.7 182.3 ± 5.8⁎ 187.3 ± 6.3⁎
Serum IL-6, pg/ml 16.4 ± 3.0 30.4 ± 5.8⁎ 28.4 ± 4.2⁎
Serum iNOS, U/ml 7.3 ± 1.3 17.8 ± 2.7⁎ 18.1 ± 2.5⁎
Plasma ET-1, pg/ml 5.2 ± 0.9 33.0 ± 5.6⁎ 30.4 ± 5.2⁎
LPS, lipopolysaccharide; BE, base excess; Lac, lactate; BP, blood pressure; FS, fractional
shortening; CPK, creatine phosphate kinase; TNF-α, tumor necrosis factor-α; IL-6,
interleukin-6; iNOS, inducible nitric oxide synthase; ET-1, endothelin 1; Data are
mean ± S.E.
⁎ p b 0.05 vs. control.
# p b 0.05 vs. LPS groups.
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Western blotting for renal HIF-1α, ECE-1, ET-A receptor, ET-B receptor
Ice-cold kidney tissues were minced with scissors, homogenized,
centrifuged and then the concentration of the protein (supernatant)
was determined using the bicinchoninic acid protein assay (Pierce Bio-
technology, Rockford, IL). Samples were boiled in reducing SDS sample
buffer for 5 min, loaded onto an SDS-PAGE (4–15% polyacrylamide) gel,
subjected to electrophoresis, and electrophoretically transferred to
polyvinylidine diﬂuoride ﬁlter membrane. To reduce non-speciﬁc bind-
ing, the membrane was blocked for 2 h at room temperature with 5%
non-fat milk in PBS (137 mM NaCl, 2.7 mM KCL, 8.1 mM Na2HPO4,
1.5 mM KH2PO4) containing 0.1% Tween 20, incubated overnight at
4 °C with primary antibodies in PBS-Tween buffer, washed three
times with PBS-Tween buffer, and then the membrane was incubated
with a suitable secondary antibody coupled to horseradish peroxidase
for 60 min at room temperature. The blots were then washed three
times in PBS-Tween buffer and subsequently visualized with an en-
hanced chemiluminescence detection system (Amersham) and exposed
to an X-ray ﬁlm (Fuji Photo Film). The intensity of total protein bands
per lane was evaluated by densitometry. Negligible loading/transfer vari-
ation was noted between samples. Moreover, beta-actin was used as a
loading control. Commercially available and well-characterized antibod-
ies were used in the present study, namely: anti-HIF-1α antibody
(Abcam, Cambridge, UK), ET-A receptor antibody (Alomone Labs, Jerusa-
lem, Israel), ET-B receptor antibody (Alomone Labs, Jerusalem, Israel) and
endothelin-converting enzyme-1 (ECE-1, Santa Cruz Biotechnology, Inc.
Europe).
RNA preparation and real-time quantitative polymerase chain reaction
Total RNA from kidney tissue was isolated using RNeasy (Qiagen,
Tokyo, Japan). After isolation, DNase I treatment, and quantiﬁcation,
RNA was reverse transcribed to cDNA by Omniscript RT using a ﬁrst-
strand cDNA synthesis kit (Qiagen). The reaction was performed at
37 °C for 60 min.
The mRNA expression levels of target genes were analyzed by
real-time quantitative PCR with TaqMan probe using an ABI Prism
7700 sequence detector (PerkinElmer Applied Biosystems, Foster, CA).
The gene-speciﬁc primers and TaqMan probes were synthesized from
Primer Express version 1.5 software (PerkinElmer) according to the
published cDNA sequences for each gene, as previously described
(Shimojo et al., 2006, 2007). The expression of GAPDH mRNA was
used as an internal control. The PCR mixture (25 μl total volume)
consisted of forward and reverse primers for each gene (PerkinElmer)
at 450 nM each, FAM-labeled primer probes (PerkinElmer) at 200 nM,
and TaqMan Universal PCRMaster Mix (PerkinElmer). Each PCR ampli-
ﬁcation was performed in triplicate as follows: 1 cycle at 95 °C for
10 min and 40 cycles at 94 °C for 15 s and 60 °C for 1 min. The quanti-
tative values of target mRNAs were normalized by GAPDH mRNA, be-
cause GAPDH mRNA expressions were more stable among all the
samples than other internal controls such as β-actin and 18S ribosomal
RNA. Primers and probes are as follows: TNF-α forward: 5′-CCAGGAGA
AAGTCAGCCTCCT-3′, TNF-α reverse: 5′-TCATACCAGGGCTTGAGCTCA-
3′, and TNF-α probe: 5′-AGAGCCCTTGCCCTAAGGACACCCCT-3′; IL-6
forward primer: 5′-ACAGCCACTGCCTTCCCTAC-3′, IL-6 reverse: 5′-
TCTCATTTCCAAGATCTCCC-3′, and IL-6 probe: 5′-CACAGAGGATACCA
CCCACA-3′; iNOS forward: 5′-GTGGGTGGCCTCGAGTTC-3′, iNOS re-
verse: 5′-CCAATCTCGGTGCCCATGTAC-3′, and iNOS probe: 5′-CTGCCC
CTTCAATGGTT-3′; HIF-1α forward: 5′-CTATGGAGGCCAGAAGAGGG
TAT-3′, HIF-1α reverse: 5′-CCCACATCAGGTGGCTCATAA-3′, and HIF-
1α probe: 5′-AGATCCCTTGAAGCTAG-3′, ET-1 forward: 5′-TCTACTTC
TGCCACCTGGACAT-3′; ET-1 reverse: 5′-GAAGGGCTTCCTAGTCCATA
CG-3′, and ET-1 probe: 5′-CATCTGGGTCAACACTCC-3′; ET-A forward:
5′-GAATCTCTGCGCTCTCAGTGT-3′, ET-A reverse: 5′-GAGACAATTTCA
ATGGCGGTAATCA-3′, and ET-A probe: 5′-CAGGAAGCCACTGCTCT-3′;ET-B forward: 5′-GCTGGTGCCCTTCATACAGA-3′, ET-B reverse: 5′-CTTA
GAGCACATAGACTCAACACTGT-3′, and ET-B probe: 5′-ATCCCCACAGAA
GCCT-3′; ECE-1 forward: 5′-TCAGACAAGTCTCCACACTCATCA-3′, ECE-1
reverse: 5′-CCAGGTTCCACATCATGTAGTTGTT-3′, and ECE-1 probe: 5′-
ACAGCACCGACAAATG-3′; GAPDH forward: 5′-GTGCCAAAAGGGTCAT
CATCTC-3′, reverse: 5′-GGTTCACACCCATCACAAACATG-3′, and probe:
5′-TTCCGCTGATGCCCC-3′.Statistical analysis
The results were expressed asmean±SE, and themeanswere com-
pared by a one-way factorial analysis of variance, followed by Scheffé's
test for multiple comparisons. Differences were considered signiﬁcant
at p b 0.05.Results
Blood gas parameters, hemodynamics, and serum inﬂammatory markers
(Table 1)
Blood gas analysiswas performed in order to determinewhether the
rats used in the present study were endotoxemic. Arterial PaO2 was
found to be signiﬁcantly reduced in LPS-administered rats and landiolol
treatment had no signiﬁcant effect on levels of arterial PaO2. Blood lac-
tate concentrationswere increased dramatically after LPSwas given and
partly normalized with the treatment of landiolol. We also assessed the
hemodynamic parameters in the rats after LPS administration. Both the
systolic and diastolic blood pressure levels were signiﬁcantly lower 3 h
after LPS administration and were unaffected by landiolol treatment.
Heart rate was signiﬁcantly increased in LPS administered group com-
pared to control group, and signiﬁcantly decreased in LPS-administered
rats treated with landiolol. % FS measured with echocardiograph was
also signiﬁcantly hyperkinetic in LPS-administered group compared to
control group. However, hyperdynamic state induced by LPS administra-
tion was signiﬁcantly normalized in LPS + landiolol group. Plasma urea
and CPK levels did not differ among the experimental groups. Serum
levels of inﬂammatory cytokines, namely, TNF-α, IL-6 and iNOS,were sig-
niﬁcantly increased after LPS administration, as determined by ELIZA.
However, landiolol treatment did not change serum levels of these cyto-
kines with statistical signiﬁcance. Plasma ET-1 levels also signiﬁcantly in-
creased in LPS and LPS + landiolol groups compared with control and
350 Y. Ogura et al. / Life Sciences 118 (2014) 347–356landiolol treatment did not have any signiﬁcant effect on the elevated
plasma ET-1 levels in endotoxemic rat.Histopathology after LPS and landiolol administration
Evaluation of renal histology using H&E stain did not reveal any ev-
idence of intraglomerular thrombosis and/or disseminated intravascu-
lar coagulation in any of the treated animals (Fig. 1). Besides, these
sections showed only minimal tubular degenerative changes, i.e., focal
tubular dilatation with mild swelling or thinning, partly detachment
of the epithelial cells at 3 h after LPS administration, as well as in the
group treated with LPS followed by landiolol administration for 3 h
(Fig. 1). There was no remarkable inﬁltration of inﬂammatory cells in
kidney tissue after LPS administration (Fig. 1).Morphologically, no obvi-
ous differenceswere recognized between renal tissues from rats treated
with LPS alone and those treated with LPS plus landiolol (Fig. 1).Biochemical investigations of renal injury parameters
To determine whether LPS caused any elevation of circulatory renal
injury parameters,we analyzed circulatory levels of BUN, creatinine and
NGAL in endotoxemic rats. Serum BUN and serum creatinine concen-
trationswere signiﬁcantly increased after LPS administration compared
to control rats. Further, landiolol treatment prevented their increase in
endotoxemic rats (Fig. 2A and B). NGAL, recently known as an early
marker of acute kidney injury (Koyner et al., 2012; Mishra et al.,
2005), exhibited a similar pattern as levels of serumBUN and creatinine.
NGAL levels in plasma and renal tissuewere signiﬁcantly increased after
LPS administration compared to control rats and normalized by
landiolol treatment (Fig. 2C and D).mRNA and protein expression levels of inﬂammatory molecules (TNF-α,
IL-6 and iNOS) in renal tissues
To assess the expression patterns of potential inﬂammatory cyto-
kines in endotoxemic renal tissues, we determined the mRNA expres-
sion and protein levels of TNF-α, IL-6 and iNOS in LPS-administered
renal tissues. Both the mRNA and protein expression levels of TNF-α,
IL-6 and iNOS were elevated in kidney tissue after LPS administration,
compared to control group (Fig. 3) and landiolol treatment only nor-
malized the elevated levels of TNF-α (Fig. 3A and B), but not the other
inﬂammatory molecules, notably IL-6 and iNOS (Fig. 3C, D, 3E and 3F).Control LPS
Fig. 1.Morphological ﬁndings by hematoxylin and eosin staining in the kidney tissues in cont
hydrochloride administration. Magniﬁcation, 400×.mRNA and protein expression levels of HIF-1α in renal tissues
To ascertainwhether LPS administration causes any hypoxia in renal
tissues,we investigated both themRNA and protein expression levels of
HIF-1α in this tissue. HIF-1αmRNA expression and protein levels were
also markedly increased after LPS administration in kidney tissues and
landiolol treatment signiﬁcantly normalized the elevated levels of
these molecules (Fig. 3G and H) at both levels, i.e., the mRNA and
protein.
Expression of ET system components in renal tissues at mRNA and protein
levels
We also sought to ascertain whether ET system components are
altered in the early hours of endotoxemic renal tissues, by investigating
the expression pattern of various components of ET system at both
mRNA and protein levels. Prepro ET-1 mRNA and ET-1 peptide levels
were found to be elevated in renal tissue after LPS administration, com-
pared to the control group. Further, landiolol treatment signiﬁcantly
ameliorated the elevated levels of these molecules of interest (Fig. 4A
and B). ET-A receptormRNA and protein expression levels in kidney tis-
sue tended to increase after LPS administration but did not reach statis-
tically signiﬁcant levels (Fig. 4C and D). ET-B receptor and ECE-1 mRNA
and protein expression levels were signiﬁcantly increased in LPS group
in renal tissues and landiolol treatment signiﬁcantly normalized these
expressions in endotoxemic rats (Fig. 4E, F, G and H).
Effects of landiolol on control rats
Finally, to determine whether landiolol treatment affects the hemo-
dynamic and ET expression in control rats, we treated control rats with
landiolol for three hours.When control rats were treatedwith landiolol,
systolic blood pressure and heart rate decreased signiﬁcantly (Fig. 5A
and C). On the other hand, regarding diastolic blood pressure and %
FS, no statistically signiﬁcant difference was found between the differ-
ent groups (Fig. 5B and D), with or without landiolol. Further, landiolol
had no effect on plasma as well as renal levels of ET-1 in the control
group (Fig. 5E and F).
Discussion
The key ﬁndings of the present study are that: 1) treatment of LPS-
administered rats with landiolol for three hours potentially normalized
the elevated levels of blood lactate and serum levels of renal injury pa-
rameters, namely creatinine and BUN, associated with NGAL, without LPS+landiolol
rol rats, 3 h after lipopolysaccharide (LPS) administration, and 3 h after LPS plus landiolol
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Fig. 2. Serum blood urea nitrogen (BUN) level (A), serum creatinine level (B), plasma neutrophil gelatinase associated lopocalin (NGAL) level (C) and renal NGAL level (D) of the control, 3 h
LPS-administered rats, and landiolol treated 3 h LPS-administered rats. Data are shown as mean ± SE (n = 15). *p b 0.05 vs. control, #p b 0.05 vs. 3 h LPS-administered rats.
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treatment only signiﬁcantly normalized renal levels of TNF-α, without
affecting renal levels of other inﬂammatory cytokines, notably IL-6
and iNOS; 3) treatment of LPS-administered rats with landiolol for
three hours potentially normalized the elevated levels of the renal
HIF-1α-ET-1-system and 4) there was minimal tissue injury in the
kidney after LPS administration, which was unaffected by landiolol
treatment.
Our preliminary time course study conducted at various time points
(0 h, 1 h, 3 h, 6 h, 10 h, 16 h, 24 h, n = 10 for each group) showed that
LPS induced high levels of plasma lactate, elevated heart rate (HR) and
increased percent of fractional shortening (% FS), i.e., a hyperdynamic
state during the early hours of endotoxemia. These elevated end-
points were greatly normalized by landiolol as early as 3 h compared
to rats administered with only LPS. This reversal of the hyperdynamic
state in endotoxemia by landiolol resulted in reduced cardiac output,
the recovery of systemic peripheral circulation and the improvement
of arterial deoxygenation during all the time points of sepsis, and conse-
quently led to an improved survival rate. Based on these earlier observa-
tions, the 3 h time point was selected to investigate in depth, the effects
of landiolol on various pathogenesis associated with organ dysfunction
in endotoxemic rats. Wu et al (2007) have previously shown that renal
peritubular capillary ﬂow is dramatically compromised and also the
mRNA expression levels of pro-inﬂammatory cytokines, such as ICAM-
1 and VCAM-1, are clearly up-regulated as early as 2 h after LPS admin-
istration, leading ultimately to renal injury (Wu et al., 2007). In addition,
Gupta et al (2007) demonstrated an obvious reduction in cortical
peritubular capillary ﬂow in the early phase of endotoxemia, that is, at
3 h post-LPS administration, using two-photon imaging (Gupta et al.,2007). These data show that an early phase of microvascular dysfunc-
tion, following LPS administration, appears to play a key role in initiat-
ing and extending tubular injury associated with signiﬁcant
inﬂammatory activation that contributes to the extension of renal dys-
function (Gupta et al., 2007). Based on these earlierﬁndings, the present
study investigated the effects of ultra-short acting drug (landiolol) on
the tissue expression of endotoxemia related potential inﬂammatory
cytokines, the HIF-1α and ET system during the early pathogenic
phase (3 h) of AKI.
We show here signiﬁcant increases in levels of serum creatinine,
BUN, NGAL and levels of renal NGAL after LPS administration, indicating
impairment of kidney function in the endotoxemicmodels. Recently, in-
crease in urinary and plasma NGAL has been reported to be a reliable
predictor of AKI progression (El Housseini et al., 2013). NGAL is
expressed in various tissues of the body, and its expression is markedly
induced in injured epithelial cells in the kidney. In the present study,
minimal renal injury at the histological level was seen at 3 h after LPS
administration. In our previous study, we showed that blood pressure
continued to decrease even at 10 h after LPS administration, using
Wistar rats (Yamaguchi et al., 2006), although the extent of decrease
was not abrupt and remarkable. It is possible that it may be the reason
why there were no remarkable histological changes in renal tissues
after LPS administration. Thus, collectively, the endotoxemic models
used in the present study had impairment of key renal function param-
eters, minimal morphological injury as well as decrease of systemic
blood pressure. In fact, the experimental investigation of sepsis-
associated AKI induced by LPS is usually of short duration due to the
high mortality associated with the doses required to induce AKI
(Sharfuddin et al., 2012). This model also tends not to recapitulate the
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sepsis, though it tends to be a vasoconstrictive one (Sharfuddin et al.,
2012). Consistentwith this earlier report, we did not observe a signiﬁcant
amount of inﬂammatory cell inﬁltration in kidney tissues after induction
of endotoxemia in the present study. In contrast, the endotoxemicmodels
used in the present study showed increase in levels of inﬂammatory cyto-
kines, such as TNF-α, IL-6 and iNOS both at circulatory and renal levels.
Consistent with our previous studies (Jesmin et al., 2004, 2006, 2007)
and earlier reports from other labs (Cohen, 2002; Norman et al., 1995),
increase in levels of plasma and renal TNF-α was noted in the earlier
hours of endotoxemia. Similarly, consistent with our previous study
(Yamaguchi et al., 2006), we also show here elevated levels of serum
and renal iNOS after LPS administration. The elevation of IL-6, as seen in
current study after LPS administration, has been supported by data from
a previous study (Song et al., 2012). Thus, in this context, an adequate in-
ﬂammatory reactionwas observedduring the early hours of endotoxemia
in the current model, both at renal and circulatory levels through upreg-
ulation of inﬂammatory cytokines. However, morphologically, remark-
able inﬂammatory cell inﬁltration was absent in the kidney tissue after
LPS administration.Consistent with previous observations, the LPS-induced endo-
toxemia in the present study resulted in a rapid and profound elevation
of plasma ET-1 at circulatory levels (Yamaguchi et al., 2006). The main
mechanism responsible for this rise is believed to be the upregulation
of ET-1 synthesis in vascular endothelia of various organs, a conse-
quence of endothelial injury (Yamaguchi et al., 2006). Importantly, plas-
ma ET-1 levels correlate positively with the severity of endotoxemia in
patients (Pittet et al., 1991) and are lower in survivors than in non-
survivors of septic shock (Takakuwa et al., 1994). The data showing
the signiﬁcant alterations in mRNA expression of ET-1 system [ET-1,
ET receptors, ECE] of kidney tissue in endotoxemia from the present
study were consistent with our previous article, where we clearly dem-
onstrated the time-dependent alteration of various components of ET
system in kidney tissues in endotoxemia (Yamaguchi et al., 2006).
Over-expression of ET-1 is sufﬁcient to induce structural and functional
changes, including glomerular and tubule-interstitial ﬁbrosis, because
ET-1 causes hypoxic injury due to the constriction of peritubular capil-
laries and stimulates mesangial cell proliferation (Richter, 2006).
Chronic ischemia and hypoxia that exist in the presence of renal in-
terstitial ﬁbrosis (RIF) increase the expression of hypoxia-inducible
355Y. Ogura et al. / Life Sciences 118 (2014) 347–356factor-1alpha (HIF-1α). In this study, we also detected the increased
expression level of HIF-1α in kidney tissue after LPS administration,
suggesting that hypoxia remained in the kidney tissues after LPS
administration.
Although both ET receptors appear to be upregulated in kidney tis-
sues after LPS administration, as revealed here, signiﬁcant elevation
was observed in the case of ET-B receptor. In fact, upregulation of the
ET signaling pathway and NF-kappaB has been shown to play an impor-
tant role in the ARF of septic shock and a potential amelioration of renal
lesions was achieved by suppressing the ET(A) and ET(B) receptors in
the renal cortex following CPU0213 medication (He et al., 2006). Thus
therapeutics focusing on the ET receptorsmay be preferable for the pre-
vention of kidney injury in sepsis.
The most important ﬁnding of the present study is data showing
amelioration of the elevated levels of the HIF-1α–ET-1 axis by landiolol
in endotoxemic renal tissues. The ultra-short-acting beta-blocker,
landiolol, which has a potent efﬁcacy and dose adjustability, was devel-
oped in Japan for the emergency treatment of tachyarrhythmias in
human and animals (Iguchi et al., 1992; Motomura et al., 1998). Recent
studies have demonstrated that co-treatment with landiolol protects
against acute lung injury and cardiac dysfunction in a rat model of
LPS-induced systemic inﬂammation (Hagiwara et al., 2009). In that
study, landiolol treatment caused a signiﬁcant reduction in serum levels
of the inﬂammation mediator, HMGB-1, as well as histological lung
damage (Hagiwara et al., 2009). However, whether landiolol has any ef-
fect on ET system in endotoxemia is yet to be demonstrated. The current
investigation is the ﬁrst to show the effectiveness of landiolol on revers-
ing the elevated levels of the HIF-1α–ET-1 system in renal tissues of
endotoxemic rats. For now, we have no obvious explanation to describe
the underlying mechanism of landiolol in reversing the elevated levels
of ET system in endotoxemic rats. It is important to note that landiolol
had no effect on the elevated plasma levels of inﬂammatory cytokines,
namely TNF-α, IL-6 and iNOS. Surprisingly, landiolol normalized the
renal augmented expression of TNF-α, but failed to normalize the ele-
vated renal levels of IL-6 and iNOS after LPS administration. The under-
lying mechanisms for the differential effects of landiolol on circulatory
and renal levels of inﬂammatory cytokines (TNF-α, IL-6 and iNOS), as
observed in the present study, for now cannot be accounted for. More
speciﬁcally, the exact process regulating reversal of elevated renal ex-
pression of TNF-α by landiolol for now is unclear, and thus warrants
in depth exploration in future studies. Also, we show that landiolol nor-
malizes the elevated levels of biochemical markers of renal injury, such
as creatinine, BUN and NGAL. The decrease in levels of renal injury pa-
rameters by landiolol indicates that it (landiolol) may be effective in
regulating the progression of renal dysfunction in sepsis. In addition,
in the present study, introduction of landiolol improved PaO2 and lac-
tate levels in LPS-administered rats, the crucial features of endotoxemia.
Thus, we believe that landiolol has reno-protective effects on endo-
toxemic kidney through the reversal of augmented levels of renal injury
parameters, up-regulated HIF-1α–ET-1 axis, and increased expression
of inﬂammatory cytokine, such as TNF-α.
The use of adrenergic antagonist with beta1-selectivity has a thera-
peutic advantage over non-selective beta-adrenergic antagonists in
the treatment of patients with peripheral vascular disease, diabetes
mellitus and obstructive pulmonary diseases (Weir et al., 2012). Recent-
ly, a lot of clinical studies have shown the efﬁcacy and safety of landiolol,
an ultra-short acting beta-1-selective blocker, on intraoperative and
postoperative tachyarrhythmias in critical conditions (Taenaka and
Kikawa, 2013), such as coronary artery bypass grafting, cardiac valve
surgery, and other thoracic surgeries (Plosker, 2013). These critical con-
ditions are vulnerable to acute tubular necrosis/acute kidney injury,
which is also associated with increased mortality. In general, the
short-term administration of a beta-blocker usually results in a reduc-
tion of GFR and effective renal plasma ﬂow (Weir et al., 2012). In con-
trast, nebivolol, a beta-1-selective blocker, has vasodilator properties
and has been shown to increase GFR and renal plasma ﬂow throughmechanism of increased synthesis of vasodilator nitric oxide (Greven
and Gabriëls, 2000). The degree of speciﬁcity of beta-adrenergic
blockers for beta-1- and beta-2-receptors might be expected to inﬂu-
ence renal function, to the same extent as intrinsic partial agonist activ-
ity (Weir et al., 2012). So far, no clinical report shows that landiolol
causes obvious renal dysfunction. However, equally, we did not
ﬁnd a clinical report that shows any safe or efﬁcacious use of
landiolol for kidney conditions in patients that have endotoxemia.
The present ﬁnding is the ﬁrst evidence that landiolol treatment in
the early hours of endotoxemia is effective in reversing the circula-
tory levels of renal injury parameters and levels of inﬂammatory
cytokines, as well as elevated HIF-ET. Future studies are needed to
clarify these issues.
Another important ﬁnding of the present study is that landiolol
only signiﬁcantly affects heart rate in both control and endotoxemic
rats. In contrast, both the circulatory and renal ET-1 levels in control
rats were not affected by landiolol. Thus, the potential reversal of
renal ET-1 levels by landiolol in endotoxemic rats, as reported
here, may be speciﬁcally attributed to landiolol in sepsis. It is impor-
tant to note that no signiﬁcant change in blood pressure of LPS plus
landiolol administered animals, implying that the normalization of
up-regulated renal ET-1 levels in endotoxemia by landiolol is inde-
pendent of blood pressure changes. In depth investigations are
warranted in the future regarding this issue.
The present study was conducted during the early hours of
endotoxemia,when the circulatory inﬂammatory cytokineswere highly
up-regulated and renal injury markers began to increase. However,
signs of renal injury at themorphological levelwere still absent or insig-
niﬁcant. On the other hand, under these conditions, levels of renal HIF-
1α and ET-1 were signiﬁcantly up-regulated in the endotoxemic rats.
Based on these data, we speculate that expression of the renal HIF-
1α–ET-1 system begins to be altered prior to the onset of obvious
renal injury in experimental endotoxemia and landiolol signiﬁcantly
amelioratesmolecular changes that arrests progression of renal damage
during sepsis.
Conclusion
Our present study shows that landiolol hydrochloride normalizes
serum levels of potential renal injury markers, renal levels of inﬂamma-
tory cytokine, such as TNF-α and up-regulated expression of HIF-1α
and ET-1 system in kidney tissues in the early hours of endotoxemia
in a rat model with a minimal/absent level of morphological renal
injury.
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